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Research Article 
Skeletal Muscle Remodelling as a Function of 
Disease Progression in Amyotrophic Lateral Sclerosis 
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Muscle weakness is considered the pivotal sign of amyotrophic lateral sclerosis (ALS). Knowledge about the skeletal muscle 
degeneration/regeneration process and the myogenic potential is limited in ALS patients. Therefore, we investigate these processes 
in a time course perspective by analysing skeletal muscle biopsies from ALS patients collected before and after a 12-week period of 
normal daily activities and compare these with healthy age-matched control tissue. We do this by evaluating mRNA and protein 
(immunohistochemical) markers of regeneration, neurodegeneration, myogenesis, cell cycle regulation, and inflammation. Our 
results show morphological changes indicative of active denervation and reinnervation and an increase in small atrophic fibres. 
We demonstrate differences between ALS and controls in pathways controlling skeletal muscle homeostasis, cytoskeletal and 
regenerative markers, neurodegenerative factors, myogenic factors, cell cycle determinants, and inflammatory markers. Our results 
on Pax7 and MyoD protein expression suggest that proliferation and differentiation of skeletal muscle stem cells are affected in ALS 
patients, and the myogenic processes cannot overcome the denervation-induced wasting. 
 
 
 
1. Introduction 
Amyotrophic lateral sclerosis (ALS), also known as motor 
 
to our knowledge, never been investigated in a time course 
perspective. 
neuron (MN) disease, is the most common motor neuron dis- Muscle weakness is considered the cardinal sign of ALS an 
order among adults [1]. ALS is characterized by degeneration 
of upper motor neurons leading to spasticity and lower motor 
neurons resulting in interruption of the nerve connection at 
the neuromuscular junction (NMJ) and myofibre loss [2, 3]. 
The affected neuromuscular system attempts to restore func- 
tion by nerve sprouting for reinnervation and by myogenesis 
to regenerate the muscle fibres [4]. Eventually, persistent mus- 
cle wasting exceeds the ability to repair and the consequence 
is progressive muscle atrophy, respiratory insufficiency, and 
usually death within 3–5 years of diagnosis [5]. Knowledge 
about the skeletal muscle degeneration/regeneration process 
and the myogenic potential is limited in ALS patients and has, 
d debate still exists as to whether denervation originates 
from the neuron or the muscle [4]. Much of our current 
knowledge about ALS disease progression is established 
within the superoxide dismutase (SOD1) G93A mouse model 
[6]. Previous studies show that muscle specific expression 
of mutant SOD1 in mice leads to an ALS phenotype and 
degradation of MNs [7, 8], demonstrating that abnormalities 
in skeletal muscle can induce degradation of MNs and cause 
ALS symptoms. 
Human ALS samples are rare, but autopsy of an ALS 
patient demonstrated skeletal muscle changes with clear signs 
of denervation and reinnervation. However, the patient had 
normal appearing motor neurons; thus pathological changes 
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2 47 <1 Spinal Walk ua Walk ww 40 38 
3 65 <1 Bulbar Walk ua Walk ua 38 36 
< 
61  ±
2.7
 
� 
isopentane.  The  samples  were  stored  at  −80 C  for  further∘ 
0.8 
� = 7 65.1 ± 
 
Table 1: Clinical characteristics of ALS patients included in the study. 
Subject Age Diagnosed Disease onset Ambulation ALSFRS-R 
1 68 < Spinal Walk ua Walk ua 42 41 Years Years BL 12 wk. BL 12 wk. 
 
1 
4 69 15 Spinal Walk wb Walk wb 38 38 
5 57 1 Spinal Walk ua Walk ww 43 40 
 
Ua: unassisted; wb: with ankle brace; ww: with walker. ALSFRS-R: ALS functional rating scale-revised. 
 
in skeletal muscle appear to be present before the motor 
neurons are affected [2], thus providing human evidence for 
the “dying-back” phenomenon. 
Healthy skeletal muscle has a remarkable ability to regen- 
erate after injury and tissue damage. The skeletal muscle 
stem cells, the satellite cells (SCs), that reside under the basal 
lamina of muscle fibres are responsible for this repair [9]. 
Upon activation, the SCs become myoblasts and proliferate 
and differentiate to restore and replace damaged muscle fibres 
[10]. In vitro cultures of SCs from ALS patients demonstrate a 
senescent-like morphology, disturbed differentiation, and an 
apparent inability to proceed through the myogenic program 
[11, 12] resulting in a decreased ability to regenerate and 
mature to functional myofibres. 
Together, these findings suggest an important role of 
skeletal muscle homeostasis, metabolic condition, and regen- 
erative ability in the development of ALS. To slow down 
disease progression, maintenance of skeletal muscle function 
may be the most promising therapeutic target as of today. 
Thus, improved knowledge about the skeletal muscle degen- 
eration/regeneration process is warranted, particularly in a 
time course perspective. 
Therefore, in the present study we describe the degenera- 
tive and regenerative processes of skeletal muscle of human 
ALS patients and how different markers change during 12 
weeks of disease progression. The hypothesis is that the myo- 
genic program is ineffective in patients with ALS compared 
with healthy age-matched subjects. 
2. Materials and Methods 
Five subjects clinically diagnosed with ALS   (aged 
yrs) agreed to participate in this study. The patients 
were diagnosed at the Department of Neurology, Odense 
University Hospital according to the El Escorial criteria [13]. 
Four of them were diagnosed within one year from inclusion, 
whereas the last one was diagnosed 15 years earlier (subject 
4, Figure 1). Inclusion criteria were definite or probable 
ALS, being ambulatory at onset of study, and willingness to 
comply with the study protocol. Patients were excluded for 
other neurological or serious medical problems including 
cardiovascular disease and diabetes mellitus. See Table 1 for 
additional clinical details. All subjects were evaluated using 
the revised ALS functional rating scale (ALSFRS-R) [14], 
which showed that all patients presented with a similar 
functional score at the time of inclusion and their disease 
symptoms showed a comparable decline over the 12-week 
period (Table 1), thus allowing us to group the patients for all 
analyses. The participants were informed about the purpose 
of the study and gave written informed consent before their 
participation. The study was conducted according to the 
Declaration of Helsinki and was approved by the Local Ethics 
Committee of the Region of Southern Denmark, Denmark. 
2.1. Sample Collection. Muscle biopsies were obtained at 
baseline (BL) and after 12 weeks (12 wk.). They were collected 
from m. vastus lateralis under local anaesthetic (1% lidocaine; 
Amgros, Copenhagen, Denmark) using a 5 mm Bergstro¨m 
needle. Biopsies were taken in the same region and depth of 
the weakest leg and care was taken to avoid any damaging 
effect of multiple biopsies [15] by separating incisions by 
about 5 cm. Fifty to hundred mg tissue was excised and 
divided into multiple pieces. These were either snap-frozen in 
liquid nitrogen or embedded in Tissue-Tek (Sakura Finetek, 
Alphen aan den Rijn, Netherlands) and frozen in precooled 
analysis. Furthermore, muscle biopsies were collected form 
healthy aged-matched control subjects (   , aged 
yrs.) using the above protocol. 
2.2. RNA Extraction and cDNA Synthesis. Tissue samples 
were homogenized and total RNA was extracted accord- 
ing to the manufacturers directions including a salt wash 
[16] and RNA concentration was measured using the Nan- 
oDrop (ND1000, Thermo Scientific, Copenhagen, Denmark) 
returning 260/280 ratios above 1.8 for all samples, and 
intact RNA was confirmed by denaturing agarose gel elec- 
trophoresis (Bioanalyzer; Agilent Technologies, Glostrup, 
Denmark). 500 ng of RNA was converted into complemen- 
tary DNA using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Copenhagen, Denmark). 
2.3. Real-Time Reverse Transcriptase Polymerase Chain Reac- 
tion. Real-time RT-PCR for ACTA1, CHRNA1, GDNF, 
CDK5, MYOG, MYOD1, NCAM, CD68, and PTPRC/CD45 
was performed using TaqMan Low Density Arrays. Each 
port on the card was loaded with cDNA equivalent to 
125 ng total RNA and run at 50 cycles in triplicate on 
the 7900 Sequence Detection System (all reagents from 
Applied Biosystems, Copenhagen, Denmark). For MYF5, 
PAX7, P21, P27, SMAD3, and IGF1 real-time RT-PCR was 
performed in reactions of 25 L by mixing 6.25 ng cDNA with 
appropriate TaqMan primers/probes and run in triplicate 
as described above. Specific primer details can be found in 
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Table S1 “(see Supplementary Material available online at 
http://dx.doi.org/10.1155/2016/5930621)”. Data was collected 
Zwijnaarde, Belgium) [17]. Data are scaled and presented 
relative to the same control sample (=1) for all  mRNA 
Δ > 0.5 �
   nd for controls. 
(Applied Biosystems). Technical  triplicates were   evaluated 
. Control genes were 
 
BL 12 wk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1: Morphological changes induced during 12 weeks of disease progression. Hematoxylin and eosin (HE) stainings of skeletal muscle 
biopsies obtained at baseline (BL) and after 12 weeks (wk.). Control samples show representative images of two healthy age-matched muscles. 
for ALS and for controls. Scale bar = 100 m. 
 
 
 
and analysed using SDS 2.4 or QuantStudio 12K software 
 
  
analyses: � = 5 � = 7  
 
 
verified using geNorm software and data were normalized to 
RPLP0 and GAPDH using the qBase+ software (Biogazelle, 
transcribed using a TaqMan MicroRNA Reverse Transcrip- 
tion Kit (4366596) and RT  primers specific for   miR-1, 
Ct and samples excluded when 2.4. MicroRNA Analysis.  Thirty g total RNA was reverse 
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(Biogazelle, Zwijnaarde, Belgium): � = 5 � = 7  
� 
Mixed (%) 4.9 ± 2.0 4.8 ± 1.5 
Type I (%) 52.5 ± 6.3 54.9 ± 9.3 
Type II (%) 42.7 ± 15 40.3 ± 7.5 
± ± 
CSA type II (�m
2 
) 3998 ± 591 3596 ± 1159 
+ + − + + 
� � 
compared to BL (#� < 0.05 
Furthermore, Pax7 cells, Pax7 /MyoD cells, Pax7 /MyoD 
± 
± 
cally transformed before statistical analysis and are reported 
-t 
analyses (GraphPad Software, version 6.0, La Jolla, USA) of 
differences between BL and 12 wk. and BL or 12 wk. and CON 
Immunohistochemical stainings for MHC-slow (type I 
 
3(a) and 3(b)), as well as areas with fibre type grouping 
dominated by either type I fibres or type II fibres (Figures 
�  <  0.05 
2 2 
, while # indicates significant difference between BL and 12 wk. in both type I and type II fibres ( ); thus ALS 
 
miR-27b, mir-133a, miR-26a, miR-206, miR-29b, miR-23a, 
miR-455, and controls RNU24 and RNU6b according to 
manufacturers instructions. The RT products were then 
amplified in triplicate using sequence complementary Taq- 
Man Small RNA assays. All reagents were from Applied 
Biosystems. Data was collected and analysed using   SDS 
2.4 and normalized to RNU24 using the qBase+ software 
for ALS and 
for controls. 
2.5. Immunohistochemistry and Quantifications. Ten m sec- 
Table 2: Fibre type distribution in ALS muscle. 
 
 
BL 12 wk. 
 
Total fibres (mean) 300.8   83.5 207   38 
 
 
CSA type I (�
�
m2
2
) 3480 
±
± 375 3116
±
± 763 
 
CSA mixed ( m ) 5807   679 3461  1040# 
tions of frozen tissue were fixed, permeabilised, and blocked 
before they were incubated with primary antibodies (1 h, 
at room temperature). Primary antibodies include MHC- 
slow 1 : 2000 (M8421, Sigma-Aldrich, Copenhagen, Den- 
mark), MHC-fast 1 : 2000 (M4276, Sigma-Aldrich), MyoD1 
1 : 25 (386R-16, Cell Marque/Sigma-Aldrich), Pax7 1 : 100 
(Hybridoma Bank, Iowa City, USA), Ki67 1 : 100 (MiB-1, 
Dako), NCAM 1 : 100 (Leu19/MY31, BD Biosciences, Albert- 
slund, Denmark), and CD68 1 : 100 (M0814, Dako). Then, 
ImmPRESS AP Ig polymer detection kit and Vector Blue or 
Vector Red AP Substrate Kit (Vector Laboratories, Herlev, 
Denmark), Envision+/DAB+ (K4001, K4003, and K3468, 
Dako, Copenhagen, Denmark), or Alexa Fluor 488 or 555 
anti-mouse or anti-rabbit, accordingly 1 : 500 (Thermo Fisher 
Scientific, Denmark), were applied according to manufactur- 
ers protocols. Immunofluorescence stainings were mounted 
with ProLong Diamond Antifade Mountant with DAPI 
(Thermo Fisher Scientific). Digital image processing and 
analyses were performed using Axio imager M1 and Axio- 
Vision by Zeiss (Brock & Michelsen, Copenhagen, Den- 
mark). 
In all quantifications the investigator was blinded to 
the identity of the patients. Cross-sectional area (CSA) of 
type I and type II muscle fibres was determined, and only 
truly transverse cut fibres were included in the analysis. The 
percentage of fibres belonging to every CSA interval was 
determined 
+
for  ea
+
ch  patient  befo
+
re  calculating  the
+
mean. 
 
    
No significant differences are observed for any parameters except for the 
cross-sectional area (CSA) of mixed fibres, which is reduced at 12 wk. 
). 
 
 
3. Results 
3.1. Visible Morphological Changes in ALS. Figure 1 shows 
HE stainings from ALS subjects at BL and 12 wk. and from 
two control samples and reveals morphological changes with 
increasingly disorganised muscle fibres including increased 
number of atrophic fibres and compensatory hypertrophy in 
all ALS biopsies. Subjects 2 and 5 are particularly affected by 
disease progression demonstrating a high degree of atrophy, 
compensatory hypertrophy, and areas of macrophage infiltra- 
tion after 12 wk., while the remaining subjects present with 
milder morphological changes including the same features. 
Furthermore, increased amounts of inflammatory cells as 
well as nuclear clumps are present between the muscle fibres 
at 12 weeks compared to BL. 
The morphological changes are supported by an increase 
in -actin (ACTA1), since -actin is known to be induced 
during active remodelling, for example, exercise and regen- 
eration [18, 19]. Furthermore, denervation is evident by 
increases in the nerve and NMJ promoting factors acetyl- 
choline receptor (CHRNA1), glial derived neurotropic factor 
(GDNF), and cyclin-dependent kinase 5 (CDK5), when 
 
 
    
At each time point � = 5 for ALS samples and � = 3–5 for 
 
3.2. Changes in Fibre  Type  Distribution and Fibre   Cross- were determined and related to the total number of fibres. 
controls due to limited control sample tissue. 
 
2.6. Statistical Analysis. Data are presented as mean SEM, 
apart from mRNA expression data, which were  logarithmi- 
in the paper as geometric means SEM (b ck-transform
 
Sectional Area. Baseline and 12 wk. biopsies demonstrate 
individual disease-induced changes in fibre type distribution 
and mean CSA, but none of the changes are significant at a 
group level (Table 2). 
fibres) and MHC-fast (type II fibres) demonstrate atrophy 
values). Paired and unpaired � ests were used for statistical 
 
and compensatory hypertrophy of both fibre types (Figures 
 
were compared using Fisher’s LSD Test. Data was considered 1000 �m to more than 10.000 �m (Figures 3(i) and 3(j)). 
for mRNA, miRNA,  and immunohistochemistry  stainings. 
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3(e)–3(h)). The distribution of individual fibre CSA displays 
large variability in fibre size with fibres raging from below 
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fibres cells, and NCAM cells, NCAM cells, MyoD /Ki67 
compared to controls (Figure 2). fibres cells, and NCAM cells, NCAM cells, MyoD /Ki67 
muscle contains a larger number of atrophic fibres at 12 wk. 
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12 wk. in ALS patients. () indicates a tendency for a significant 
difference from controls; , 
 
difference (� < 0.1). 
, and and 12 wk. there is a shift towards a smaller fibre size after 
 
compared to BL. 
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∗∗∗ 
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∗∗∗ 
∗ 
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to age-matched controls (#� < 0.1 compared to BL). Asterisks indicate significant difference from controls; ∗� < 0.05 and ∗∗∗� < 0.001. receptor (CHRNA1) (b), glial derived neurotropic factor (GDNF) (c), and cyclin-dependent kinase 5 (CDK5) (d) at BL and 12 wk. compared 
+ 
+ 
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NCAM cells are observed (Figures 5(e) and 5(f)). 
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Figure 2: Evidence of skeletal muscle remodelling and motor neuron denervation. mRNA levels of �-actin (ACTA1) (a), acetylcholine 
 
 
 
3.3. Myogenic Changes in ALS. Skeletal muscle of ALS 
patients shows a reduction in mRNA levels of satellite cell 
 
 
4(g) and 4(j)). To evaluate whether these MyoD+ cells were in an a
+
ctive pro
+
liferative state or postmitotic, we performed 
 
and early myogenic markers PAX7 and MYF5  compared a Ki67  /MyoD   double immun
+
ofluorescence staining. Here 
markers myogenin (MYOG) and MYOD1 are increased 
(Figures 4(a)–4(d)). The mRNA levels of MYOG and MYOD1 
are increased at 12 wk. compared to BL, although this does not 
reach statistical significance. 
The mRNA results suggest that the satellite cells might be 
affected in the ALS patients. We therefore analysed the activa- 
tion status of the satellite cells using immunohistochemistry. 
  
 
general there were almost no Ki67 expressing cells in the 
tissue (Table 3 and Figures 4(j)–4(l)). 
To further evaluate myogenic changes in ALS muscle 
we analysed expression of NCAM. We observe that NCAM 
mRNA levels are highly increased in ALS compared to 
controls (Figure 5(a)). Immunohistochemistry for NCAM 
protein demonstrates NCAM expression in both single cells 
 
 
ures 4(e) and 4(f), arrows) and in smaller fib
+
res (Figure 4(f), 
whether the satellite cells are activated or are resting we 
 
  
ures 5(b) and 5(c)), whereas controls show a few NCAM 
 
to reach
+
statistical significance (� = 0.078), but no changes in 
 
satellite cells (Pax7 /MyoD ); thus the majority of the Pax7 
and individual fibres, which are mainly atrophic fibres (Fig- cells were found next to both hypertrophied fibres (Fig- Pax7 
to controls, whereas the mRNA levels of the late myogenic 
(d) (c) 
we found that very few MyoD cells expressed Ki67, and in 
arrowhead). The overall number of  Pax7 cells/fibre did satellite cells (Figure 5(d)). The disease progression induces a 
decrease in NCAM fibres for all ALS subjects, which trends 
3.4.  Alterations  in  myomiRs,  Cell  Cycle  Regulators, and 
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+ 
not change between BL and 12 wk. (Table 3). To investigate 
performed double immunofluorescence staining for Pax7 and 
MyoD
+
. We fin
+
d that that very few Pax7   cells e
+
xpress MyoD 
are negative for MyoD (Table 3 and Figures 4(g)–4(i)). On 
an interesting note, we observed a large amount of MyoD 
positive nuclei in the tissue in general for all patients (Figures 
Inflammation in ALS. Skeletal muscle specific microRNAs 
(myomiRs) 1, 26a, and 133a along with miR-455 are reduced 
in ALS compared to controls (Figure 6(a)); however, disease 
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Figure 3: Skeletal muscle of ALS patients presents with atrophy of both type I and type II fibres. (a and b) Representative images of 
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progression does not induce further change between BL 
and 12 wk. mRNA expression of cyclin-dependent kinase 
inhibitor 1A (p21) is induced, while cyclin-dependent kinase 
inhibitor 1B (p27) and mothers against decapentaplegic 
homolog 3 (SMAD3) mRNA transcripts are reduced com- 
pared with controls (Figures 6(b)–6(d)). Insulin-like growth 
factor 1 (IGF1), an inducer of muscle tissue growth, is not 
affected in ALS compared to controls (Figure 6(e)). Both 
mRNA levels of CD68 and CD45 along with protein expres- 
sion of CD68 demonstrated higher levels of inflammatory 
cells in skeletal muscle of ALS patients compared to controls 
 
(Figure 7). The CD68 cells were localized mainly in the 
connective tissue between muscle fibres. 
 
4. Discussion 
In this paper we describe the degenerative and regenerative 
processes in skeletal muscle of ALS patients over a short- 
term period to observe disease development and progression. 
Moreover, we compare the skeletal muscle of ALS patients to 
that of healthy, age-matched muscle. We find morphological 
changes in ALS muscle indicative of active denervation and 
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reinnervation along with a reduction in CSA, yet none of 
the examined mRNA markers change significantly within the 
12-week time period. However, we demonstrate differences 
between ALS and controls in pathways controlling skeletal 
muscle homeostasis, cytoskeletal and regenerative markers, 
neurodegenerative factors, myogenic factors, cell cycle deter- 
minants, and inflammatory markers. 
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morphological changes, revealing a preferential type II fibre 
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Table 3: Analysis of activation status of satellite cells in ALS. 
Subject Pax7 Pax7 /fibre Pax7 /MyoD Pax7 /MyoD Ki67 /MyoD 
BL 
1 13 0.071 12 2 1 
2 32 0.066 30 2 2 
3 26 0.074 23 3 0 
4 11 0.092 11 0 1 
5 22 0.068 22 0 0 
Mean  SEM 20.8   3.9 0.074   0.005 19.6   3.6 1.4   0.6 0.8   0.37 
 
12 wk. 
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2 10 0.067 9 1 0 
3 21 0.088 21 0 1 
4 23 0.099 23 0 0 
5 25 0.091 25 0 0 
Mean  SEM 17.8   3.25 0.080   0.01 17.4   3.5 0.4   0.2 0.2   0.2 
 
Satellite cells/myoblast in BL and 12 wk. patient samples were stained for expression of Pax7, MyoD, and Ki67 using immunofluorescence and evaluated by 
counting. The number of identified cells in each section is noted. 
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[21] and neuromuscular disorders [22] and described char- 
acteristic features as a mix of the above with muscle fibre 
atrophy and hypertrophy and a large degree of fibre type 
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  of either an exhausted or an impaired regeneration. It must NCAM mRNA levels compared to controls, and high muscle 
BioMed Research International 13 
 
∗∗∗ 
∗∗∗ 
∗∗∗ ∗∗∗ 
Scale bar = 50 �m. 
� = 5 � = 7 � = 5 ∗∗∗� < 0.001 
+ 
+ 
+ 
round [25]. We find that NCAM fibres in ALS patients 
denervated fibres rather than newly formed, regenerating marker Ki67 reveals that only few of the MyoD cells are in an 
As a measure of the myogenic potential we evaluated cells are kept in a MyoD postmitotic state. Whether this is 
young and old individuals to be around 0.05 Pax7 cells/fibre that both MYOD1 and MYOG are regulated by  electrical 
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be kept in mind that it is the number of NCAM fibres that 
have been evaluated, rather than the expression level of each 
fibre, which might change over time. 
Denervated, atrophic myofibres tend to become angular 
and eventually result in “nuclear clumps” with little or no 
 
 
cells to regenerate the muscle; however, this process has 
somehow been halted or distorted due to the ALS pathology. 
The higher expression levels of MYOD1 and MYOG 
mRNA in ALS muscle could indicate an activated differentia- 
tion process. When analysing expression of MyoD on protein 
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the same magnitude in ALS patients [27]. stimulation [29]; thus the findings on changes in MyoD on 
[26], indicating that satellite cells are present for potential 
activation [28]. We therefore performed double stainings for 
MyoD an
+
d  Pax7 to evaluate the actual activation status of 
neural activity in these patients. The observation of reduced 
early myogenic markers in combination with increased late 
myogenic markers probably reflects the disease pattern in 
 
cells are in a nonactive, resting state and are not activated. However, since we find the presence of many MyoD /Ki67 cells, this 
skeletal muscle of ALS patients. 
Denervation is one of the earliest signs of ALS and in line 
satellite cells in ALS skeletal muscle. the number of Pax7 
due to a long differentiation period or the cells are arrested at the number of Pax7 
cells in general, level we observe a high amount of MyoD cytoplasm left [24], while new myogenic fibres are small and 
cytoplasm left [24], while new myogenic fibres are small and 
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points out that there has been activation of satellite with this the denervation-induced markers CHRNA1, GDNF, 
and CDK5 are all highly expressed in the ALS patients as we 
expected. The sensitive nature and large increase of CHRNA1, 
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+ − 
− 
 
GDNF, and CDK5 in ALS muscle allow these to be potential 
biomarkers of ALS disease development and progression. 
In the present study we also investigated the mechanisms 
of cell cycle progression and skeletal muscle growth to evalu- 
ate if disturbances in the expression of myomiRs or cell cycle 
regulators could influence the remodelling and regeneration 
capacity of ALS skeletal muscle. MicroRNAs are tight regula- 
tors of cell fate and tissue homeostasis [30], and our results 
show that miR-1, miR-133a, and miR-206 are all reduced 
in ALS muscle suggesting that both myogenic proliferation 
and differentiation might be altered. Inhibition of miR-1 
and miR-206 blocks the downregulation of most targets in 
differentiating cells, thus indicating that they are required 
for muscle differentiation [31], while miR-133 expression is 
attenuated during the early stage of muscle regeneration and 
represses myoblast proliferation [32]. MiR-206 has also been 
identified as an important player in the repair of the NMJ 
following nerve injury [33], and one study has identified miR- 
206 as a potential disease marker in SOD-1 mice and ALS 
patients [34]. Thus miRs appear to be important players in 
ALS disease progression and muscle restoration. 
Multiple studies have identified interactions between 
miR-1 and IGF-1 showing an inverse relationship between 
these [35, 36]. We observed a reduction in miR-1 combined 
with no change in IGF-1 mRNA, which may be due to an 
insufficient reduction of miR-1, or the interactions between 
miR-1 and IGF-1 do not play a role in ALS. 
We find that p21 mRNA expression is induced in the 
ALS patients, suggesting that myogenic cells have entered the 
differentiation and maturation process and thus no longer 
proliferate [37–39]. This is supported by our findings of 
MyoD /Ki67 cells. Likewise, our data show a reduction in 
p27 mRNA in ALS patients compared to controls [40, 41], 
which is in line with our findings of the presence of primarily 
nonactivated satellite cells. 
The present study has several limitations. The small 
number of ALS patients studied here and the heterogeneous 
disease progression and clinical presentation seen in ALS 
patients in general limit our ability to generalise our findings 
to larger populations of ALS patients. However, a major 
strength of the present study is the longitudinal collection of 
muscle biopsies, which is unique in ALS patients. 
Altogether, our results suggest that activation, prolifer- 
ation, and differentiation of skeletal muscle stem cells are 
affected and possibly halted in ALS patients and there is 
therefore a generally insufficient myogenesis that cannot 
overcome the denervation-induced wasting. It would there- 
fore be necessary to understand which mechanisms are 
affected in order to impact on the myogenic program if we are 
to diminish disease progression and skeletal muscle atrophy 
in ALS patients in the future. 
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